Redeye sees another strong quarter for OssDsign as sales beat our estimates with a continuing robust...
Raute reports Q4 results on Feb 13. FY’24 already showed strong results, while low valuation limits ...
Beat in Q4 driven by higher sales EBIT +7% vs ABGSCe Estimates likely to be revised up 2-5% on EBIT ...
Redeye is encouraged by the healthy rebound in demand witnessed in Ependion’s Q4 report.
Ahead of Taaleri's Q4 results, we revise our underlying estimates to reflect Taaleri's sale of its s...
DT reports Q4 results on Feb 6. We make limited estimate revisions ahead of the report as outlook re...
Dovre completed its segmental sale for a significant cash pile, the eventual use of which remains an...
SRV reports its Q4 figures on 6th of February. We expect slight improvement in adj.
Redeye updates its estimates and valuation on Embracer to reflect the Asmodee spin-off and the stron...
Redeye comments on the ongoing launch in Norway of Terclara.
Solwers published a profit warning on Saturday 1 February, stating that Q4 2024 EBIT is close to ze...
Redeye updates its estimates and valuation following MedCap releasing its Q4 2024 report.
Redeye's view is that Lagercrantz reported another strong quarter in a challenging market.
Redeye is happy to see surprisingly upbeat numbers from Ependion.
Redeye changes its Base Case and forecasts following a strong end to a solid 2024 from Addnode.
